Gilead cleared to restart trials of CD47 drug magrolimab

Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion 

Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill...

Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.

2nd Macrophage-directed Therapies Summit

Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond

ALX Oncology cancer drug claims two FDA fast-track reviews